Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Stock
Key stats
- Market cap
- $122.73M
- Price / Earnings ratio
- -4.8x
- EPS (TTM)
- -$0.24
- Volume
- Loading
- 52-week high
- $2.34
- 52-week low
- $0.88
Source: third-party data provider, as of November 13, 2026
Compare with CRDL
Recent news

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
CRDL

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
CRDL

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
CRDL

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
CRDL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.36
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.13
- MACD histogram
- 0.01
- SMA 50
- $1.46
- Price below SMA 50
- EMA 50
- $1.30
- Price below EMA 50
- SMA 200
- $1.30
- Price below SMA 200
- EMA 200
- $1.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
CRDL

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
CRDL

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
CRDL

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
CRDL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Cardiol Therapeutics Inc. Class A Common Shares
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David G. Elsley MBA | President, CEO & Director | — |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA | CFO, Corporate Secretary & Director | — |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer | — |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development | 1962 |
| Trevor Burns | Investor Relations | — |
| Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.36
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.13
- MACD histogram
- 0.01
- SMA 50
- $1.46
- Price below SMA 50
- EMA 50
- $1.30
- Price below EMA 50
- SMA 200
- $1.30
- Price below SMA 200
- EMA 200
- $1.28
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $9.50
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +6.5 | -22.8 | -28.8 | -2.9 |



